Aristides Capital LLC Fate Therapeutics Inc Transaction History
Aristides Capital LLC
- $260 Million
- Q4 2024
A detailed history of Aristides Capital LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Aristides Capital LLC holds 100,555 shares of FATE stock, worth $117,649. This represents 0.06% of its overall portfolio holdings.
Number of Shares
100,555Holding current value
$117,649% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding FATE
# of Institutions
164Shares Held
101MCall Options Held
71.3KPut Options Held
15.9K-
Redmile Group, LLC San Francisco, CA12.9MShares$15.1 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$12.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$11.8 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$5.66 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$5.13 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $113M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...